Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. More Details
Reasonable growth potential and fair value.
Share Price & News
How has Amneal Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AMRX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: AMRX's weekly volatility (7%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: AMRX underperformed the US Pharmaceuticals industry which returned 16.9% over the past year.
Return vs Market: AMRX underperformed the US Market which returned 39.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Amneal Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StIs Amneal Pharmaceuticals (NYSE:AMRX) A Risky Investment?
2 months ago | Simply Wall StIf You Had Bought Amneal Pharmaceuticals (NYSE:AMRX) Stock A Year Ago, You Could Pocket A 128% Gain Today
3 months ago | Simply Wall StWhat Percentage Of Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Shares Do Insiders Own?
Is Amneal Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AMRX ($5.2) is trading below our estimate of fair value ($19.58)
Significantly Below Fair Value: AMRX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AMRX is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: AMRX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AMRX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AMRX is good value based on its PB Ratio (2.4x) compared to the US Pharmaceuticals industry average (3.3x).
How is Amneal Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AMRX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: AMRX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: AMRX's is expected to become profitable in the next 3 years.
Revenue vs Market: AMRX's revenue (2.4% per year) is forecast to grow slower than the US market (9.4% per year).
High Growth Revenue: AMRX's revenue (2.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AMRX's Return on Equity is forecast to be very high in 3 years time (57.8%).
How has Amneal Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AMRX is currently unprofitable.
Growing Profit Margin: AMRX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AMRX is unprofitable, and losses have increased over the past 5 years at a rate of 52.2% per year.
Accelerating Growth: Unable to compare AMRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AMRX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (0.6%).
Return on Equity
High ROE: AMRX has a negative Return on Equity (-10.11%), as it is currently unprofitable.
How is Amneal Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: AMRX's short term assets ($1.6B) exceed its short term liabilities ($636.8M).
Long Term Liabilities: AMRX's short term assets ($1.6B) do not cover its long term liabilities ($2.9B).
Debt to Equity History and Analysis
Debt Level: AMRX's debt to equity ratio (744.6%) is considered high.
Reducing Debt: AMRX had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Debt Coverage: AMRX's debt is not well covered by operating cash flow (16.9%).
Interest Coverage: AMRX is unprofitable, therefore interest payments are not well covered by earnings.
What is Amneal Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AMRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AMRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AMRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AMRX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: AMRX is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AMRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Chirag Patel (53 yo)
Mr. Chirag K. Patel has been Co-Chief Executive Officer and President of Amneal Pharmaceuticals, Inc. since August 3, 2019. Mr. Patel Co-founded Amneal Pharmaceuticals LLC in 2005 and serves as Director an...
CEO Compensation Analysis
Compensation vs Market: Chirag's total compensation ($USD2.32M) is below average for companies of similar size in the US market ($USD3.72M).
Compensation vs Earnings: Chirag's compensation has increased whilst the company is unprofitable.
Experienced Management: AMRX's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Experienced Board: AMRX's board of directors are considered experienced (3.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Amneal Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Amneal Pharmaceuticals, Inc.
- Ticker: AMRX
- Exchange: NYSE
- Founded: 2002
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$1.619b
- Market Cap: US$773.347m
- Shares outstanding: 300.84m
- Website: https://www.amneal.com
Number of Employees
- Amneal Pharmaceuticals, Inc.
- 400 Crossing Boulevard
- 3rd Floor
- New Jersey
- United States
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeut...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/19 07:09|
|End of Day Share Price||2021/06/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.